Adocia presents its AdoXLong platform at ObesityWeek, targeting a monthly injection

Extending the action of metabolic peptides up to one month

According to Adocia, AdoXLong aims to extend the duration of action of GLP-1 agonists, amylin, or other metabolic peptides currently administered weekly, in order to achieve a once-monthly injection. The company presents this objective as the answer to “a major challenge” in the treatment of diabetes and obesity.

Beyond patient convenience, a monthly formulation “aims to reduce the currently very high discontinuation rate of these treatments within the first year.” The company points out that the long-term metabolic effects of these molecules disappear if treatment is interrupted.

From a technical standpoint, the platform relies on a biocompatible polymer chemically linked to the peptides without altering their mechanisms of action. It is designed to provide prolonged circulation of the peptide for at least one month.

It can be applied to GLP-1, GIP, amylin, or dual and triple agonists, such as semaglutide, tirzepatide, or cagrilintide, with the possibility of combining these modified peptides with one another. It targets both innovative peptides and biosimilars, including semaglutide, which will be off-patent from 2026 in certain territories.

Patent application filed and first in vitro results on retatrutide

Adocia filed a patent application for AdoXLong in November 2025. Subject to grant, it would provide worldwide protection until 2046, and the peptides to which the technology would be applied would see their intellectual property extended until the same expiry date.

The company also reports positive preliminary in vitro results obtained with AdoXL Retatrutide, which it presents as confirmation of the platform nature of AdoXLong. It states that it intends to continue developing the technology “to move toward the clinic.”

The poster, titled “AdoXLong: A Long-Acting Peptide Platform Enabling Once-Monthly Administration of Incretins,” will be presented by Martin Gaudier on November 14, 2026, from 7:30 p.m. to 8:30 p.m., Washington time.

In the disclaimer accompanying the press release, Adocia draws investors’ attention to the risks related to its short- or medium-term working capital requirements and its ability to raise additional funds. AdoXLong is one of the company’s four technology platforms, alongside BioChaperone, AdOral, and AdoShell.